Navigation Links
Sigma Life Science Launches CRISPR/Cas Genome Editing Tools
Date:8/27/2013

ST. LOUIS, Aug. 27, 2013 /PRNewswire/ -- Sigma-Aldrich® Corporation (Nasdaq: SIAL) today announced that Sigma® Life Science, its innovative biological products and services business, released Sigma CRISPRs, an inexpensive mammalian genome editing tool suitable for screening and exploratory studies. Sigma CRISPRs are packaged in a single plasmid vector containing GFP for fast enrichment of gene-edited cells and can be custom-designed online using an exclusive bioinformatics tool at www.sigma.com/crisprs.

Derived from bacterial and archaeal immune defenses, which guard against invading viruses and foreign DNA, Sigma CRISPRs utilize customizable RNA–nuclease complexes that allow introduction of genome edits at a desired site in mammalian genomes with high efficiency.

Sigma's exclusive online design tool allows users to identify the best target site(s) within human, mouse, and rat protein-coding exons that adhere to CRISPR/Cas targeting requirements. It is the only commercial tool that minimizes the possibility of off-target effects by automatically applying CRISPR/Cas best design practices, including a minimum requirement of three base-pair mismatches between the target site and other sites in the genome. Researchers can also request CRISPR/Cas targets derived from their own design preferences or they can engage Sigma's expert CompoZr® Zinc Finger Nuclease (ZFN) bioinformatics team to produce a custom design based on cutting-edge public and proprietary CRISPR guidelines.

"Sigma developed CompoZr ZFN technology in 2008, and now ZFNs are the gold standard in genome editing.  We have used that expertise to create Sigma CRISPRs, which provide researchers a quicker and more affordable way to screen genes of interest.  After important targets have been identified with Sigma CRISPRs, the biologically relevant mutations can be validated with ultra-specific CompoZr ZFNs to reduce potential off-targeting," said Shawn Shafer, Ph.D., Functional Genomics Market Segment Manager at Sigma Life Science.

"The ability to manipulate mammalian genomes is transformative for biology. The Sigma CRISPR/Cas technology holds significant promise for development and use as an early, inexpensive tool for targeted gene editing," said Greg Davis, Ph.D., Principal Investigator, R&D at Sigma-Aldrich, whose team is actively working to advance the technology.

For more information, visit www.sigma.com/crisprs.

Cautionary Statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "inexpensive," "affordable," "quick-to-order," "high efficiency," or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that these Sigma CRISPRs or related services will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding products associated with Sigma CRISPRs or related services could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich:  Sigma-Aldrich, a leading Life Science and High Technology company focused on enhancing human health and safety, manufactures and distributes more than 200,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units – Research, Applied and SAFC Commercial – Sigma-Aldrich is committed to enabling science to improve the quality of life. The Company operates in 38 countries, has more than 9,000 employees worldwide and had sales of $2.6 billion in 2012. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.

Sigma-Aldrich, Sigma and CompoZr are trademarks of Sigma-Aldrich Co, LLC registered in the US and other countries.


'/>"/>
SOURCE Sigma-Aldrich Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
2. NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio
3. NeuroSigma Receives Global Quality Control Certification
4. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
5. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
6. Sigma-Aldrich Corporation To Present At Upcoming Investor Conferences
7. NeuroSigma Receives CE Certification
8. Sigma-Aldrich Enhances Customer Focus in China - Unveils Dynamic New Website and Expands Product Offering Through Vetec Brand
9. Sigma-Aldrich (NASDAQ: SIAL) Declares $0.20 Quarterly Dividend
10. Sigma-Aldrich Aligns Into Three New Market-Focused Business Units
11. Sigma-taus Antimalarial Awarded "Project of the Year" 2011 by Medicines for Malaria Venture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , January 17, 2017 ... to potentially earn millions in revenue with the planned ... massive numbers of strokes with a simple test that ... Companies with latest developments in the markets today include: ... (NYSE: AZN ), Cancer Genetics, Inc. (NASDAQ: ...
(Date:1/17/2017)... 17, 2017 Catherine ... http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ...      (Logo: ... European Neurological Review , ... Amey reports that despite standard care, temperatures ...
(Date:1/17/2017)... 17, 2017  The pioneer in no-touch UV disinfection has ... Tru-D SmartUVC , short for "total room ultraviolet disinfection," was ... Terminal Room-Disinfection (BETR-D) study which was recently published in ... that Tru-D can cut transmission of four major superbugs by ... to market in 2007, we have been committed to innovation ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Etymotic Research, ... GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF SHOT Show on January 17-20, ... The SHOT Show is the shooting, hunting and outdoor trade show and conference ...
(Date:1/16/2017)... ... 16, 2017 , ... As New York’s fastest growing ophthalmic ... to their medical staff, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief ... division of SightMD. Dr. Giamos will practice primarily out of SightMD’s Riverhead, Southampton, ...
(Date:1/16/2017)... ... ... are well-aware of the following facts at present:, Flu and ... no effect on keeping this particularly bad strain of the flu away , ... sniffling , These facts are well-known among the team at Woodard! About ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... One thing ... only to treat, but to test for, as well. The money spent screening for ... year.(1) Doctors in the U.S. screen patients for cancer more than in any other ...
(Date:1/15/2017)... ... , ... In this role, Courtney will be responsible for developing new business ... friendly mark. This certification program was created by ASL and the nonprofit Asthma and ... suitable for the 60+ million people living in the U.S. with asthma and allergies. ...
Breaking Medicine News(10 mins):